Summary: Kidney-transplant recipients appear to be at particularly high risk for critical Covid-19 illness due to chronic immunosuppression and coexisting conditions. With regard to COVID-19, all kidney transplant recipients must strictly follow the general hygiene measures recommended for the general population, including frequent hand washing, social distancing measures and wearing of masks in crowded places. COVID-19 induces variable clinical courses in normal hosts but seems to progress more rapidly in immunocompromised hosts, with greater rates of intensive care unit admissions and death. Modification of immunosuppressive therapy in SARS-CoV-2 infected kidney transplant recipients based of Descartes ERA-EDTA guidelines were presented. Controversies on CNI, steroids and hydroxychloroquine or chloroquine, in combination with a second-generation macrolide were discussed. The series of COVID-19 reported to date from Europe and the USA were presented. These articles describe various strategies for the management of immunosuppressive therapy, based on a stepwise reduction of immunosuppression according to the severity of the disease.